

12/Election
w/traverse

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN THE APPLICATION OF:
WANG, PANCRAS C.

CASE NO.: PH-7038

SERIAL NO.: 09/519,288

GROUP ART UNIT: 1614

FILED: MARCH 6, 2000

EXAMINER: KIM, V.

FOR: Treatment of Thrombosis by Combined Use of a Factor Xa Inhibitor and Aspirin, Tissue Plasminogen Activator (TPA), a GPIIb/IIIa Antagonist, Low Molecular Weight Heparin or Heparin

RECEIVED

JUN 04 2002

TECH CENTER 1600/2900

Ref
6-18-02

Dated: May 21, 2002

Hon. Assistant Commissioner for Patents
Washington, D.C. 20231

**COPY OF PAPERS
ORIGINALLY FILED**

Sir:


RESPONSE TO ELECTION OF SPECIES REQUIREMENTS

Responsive to the Official Action dated April 9, 2002, Applicant elects, with traverse, the species of Example 1, the combination of aspirin and a Factor Xa inhibitor, for examination purposes only. Claims 1-3 and 8 are readable thereon. Applicant understands this requirement for election of species to be for examination purposes only, in accordance with MPEP §803.02, and this should not be a requirement to restrict the scope of the generic claims of this application to such species.

If the Office Action is a requirement to restrict the scope of the generic claims to the elected species, Applicants traverse this requirement. Such a requirement would be improper, for the reasons stated in MPEP §803.02, first paragraph. Upon a finding that the elected species is patentable, the search should be extended to cover the non-elected species.

In view of the foregoing, Applicants submit that the application is now in condition for allowance. Early notification of such action is earnestly solicited.

Respectfully submitted,



Jing S. Belfield, Ph.D.
Agent for Applicant
Registration No. 45,914
302 467-5262

Bristol-Myers Squibb Company
c/o Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000